|
|
|
12.01.26 - 11:09
|
Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales (ZeroHedge)
|
|
|
Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales
The global pharmaceutical industry's revenue is increasingly concentrated in a handful of high-value drug classes, with oncology, diabetes/obesity treatments and immunology leading the charge.
As Statista's Tristan Gaudiat details below, according to estimates from Statista Market Insights, cancer drugs alone generated over $217 billion last year, making oncology the largest therapeutic segment, driving nearly one-fifth (18 percent) of all pharmaceutical sales.
You will find more infographics at Statista
Antidiabetic medicines rank second, with estimated sales of over $85 billion in 2025, contributing 7 percent to global market revenues.
Some of the top-grossing drugs include Merck's Keytruda, an immunotherapy for multiple cancers with almost $30 billion in revenue in 2024, as well as Eli Lilly's Mounjaro and Novo Nordisk's Ozempic/Wegovy, used for diabetes treatment and weight loss, and bringing in more than $10 billion annually for th...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 13:12
|
Schwerer Start für neuen Novo-Chef – Wegovy-Hersteller senkt erneut Prognose (Cash)
|
|
|
Der dänische Pharmakonzern Novo Nordisk hat nach einem Gewinneinbruch im dritten Quartal seine Prognose für das laufende Jahr erneut gesenkt. Für den neuen Konzernchef Mike Doustdar, der erst im August das Ruder übernommen hat und einen Sanierungsplan mit Stellenstreichungen vorantreibt, ist das ein Rückschlag. Als Grund nannte er geringere Wachstumserwartungen für die wichtigen GLP-1-Medikamente gegen Diabetes und Adipositas wie die Abnehmspritze Wegovy..
|
|
|
|
|
05.11.25 - 11:48
|
Ozempic maker Novo Nordisk cuts sales and profit forecasts again (The Guardian)
|
|
|
Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug marketThe maker of the weight-loss drugs Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments.Novo Nordisk's chief executive, Mike Doustdar, who took the reins in August, said the reduced guidance was because of “the lower growth expectations for our GLP-1 treatments”. Continue reading......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
